Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Other Operating Expenses (2021 - 2025)

Palisade Bio has reported Other Operating Expenses over the past 9 years, most recently at -$3.6 million for Q4 2025.

  • Quarterly Other Operating Expenses fell 158.13% to -$3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.6 million through Dec 2025, up 60.81% year-over-year, with the annual reading at -$7.6 million for FY2025, 38.37% down from the prior year.
  • Other Operating Expenses was -$3.6 million for Q4 2025 at Palisade Bio, down from -$1.5 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $30.1 million in Q2 2021 and troughed at -$15.1 million in Q3 2024.
  • The 5-year median for Other Operating Expenses is -$1.4 million (2024), against an average of $440000.0.
  • Year-over-year, Other Operating Expenses crashed 212.07% in 2024 and then surged 89.94% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $30.1 million in 2021, then plummeted by 98.64% to $410000.0 in 2022, then soared by 200.98% to $1.2 million in 2023, then crashed by 212.07% to -$1.4 million in 2024, then crashed by 158.13% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Other Operating Expenses are -$3.6 million (Q4 2025), -$1.5 million (Q3 2025), and -$1.1 million (Q2 2025).